Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances
May 14, 2024 16:01 ET
|
Allarity Therapeutics, Inc.
- Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved - On Track to Regain Compliance with All Nasdaq Listing Requirements - No Variable Priced Securities are...
SKYX Reports Record First Quarter Sales of $19.0 Million Compared to $18.6 Million for First Quarter 2023 as it Continues to Grow its Market Penetration in the U.S and Canada of its Advanced and Smart Platform Products
May 14, 2024 16:01 ET
|
SKYX Platforms Corp.
SKYX Reports Record First Quarter Sales of $19.0 Million Compared to $18.6 Million for First Quarter 2023
BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million
May 14, 2024 16:01 ET
|
Biostem Technologies
BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
May 14, 2024 16:01 ET
|
ProMIS Neurosciences Inc.
CAMBRIDGE, Massachusetts and TORONTO, Ontario, May 14, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and...
Capital Southwest Announces Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2024 and Announces Total Dividends of $0.63 per share for the Quarter Ending June 30, 2024
May 14, 2024 16:01 ET
|
Capital Southwest Corporation
DALLAS, May 14, 2024 (GLOBE NEWSWIRE) -- Capital Southwest Corporation (“Capital Southwest,” “CSWC” or the “Company”) (Nasdaq: CSWC), an internally managed business development company focused on...
scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 16:01 ET
|
scPharmaceuticals, Inc.
Generated 1Q 2024 net FUROSCIX® revenue of $6.1 million, despite an estimated 10% impact to doses filled resulting from the Change Healthcare cyberattack Ended 1Q 2024 with cash and cash equivalents...
American Shared Hospital Services Reports First Quarter 2024 Financial Results
May 14, 2024 16:01 ET
|
American Shared Hospital Services
American Shared Hospital Services Reports First Quarter 2024 Financial Results
Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 14, 2024 16:01 ET
|
Taysha Gene Therapies, Inc.
Completed dosing in cohort one (low dose, 5.7x1014 total vg) of REVEAL Phase 1/2 adolescent and adult trial with longer-term data supporting the safety profile and durable response of TSHA-102;...
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 14, 2024 16:01 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
OptimizeRx Reports First Quarter 2024 Financial Results
May 14, 2024 16:01 ET
|
OptimizeRx Corporation
Q1 revenue of $19.7 million, increasing 51% year-over-yearQ1 gross profit increased 64% year-over-year to $12.2 million with a gross margin of 62%Won 9 DAAP deals during Q1 WALTHAM, Mass., May 14,...